Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and Therapy
ZEPIZURE®, based on the ZENEO® autoinjector and previously known as ZENEO® Midazolam, provides for needle-free delivery of midazolam with significant associated advantages.
- ZEPIZURE®, based on the ZENEO® autoinjector and previously known as ZENEO® Midazolam, provides for needle-free delivery of midazolam with significant associated advantages.
- In addition, ZEPIZURE® enhanced the midazolam absorption during the first minutes post-injection, suggesting that seizure treatment may be efficient sooner.
- The maximum blood concentration reached with ZEPIZURE® is not above that with Dormicum®, which is a good indication in terms of safety.
- “The detailed clinical results published today in Neurology and Therapy on ZEPIZURE® are exciting, as they outline quick delivery of a life-saving medicine,” said Patrick Alexandre, CEO of Crossject.